FDA-Drug2026-01-14Class II
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Imprimis NJOF, LLC
Hazard
Presence of particulate matter - Glass like particles.
Sold states
U.S Nationwide
Affected count
314 boxes of 6,280 pre-filled syringes
Manufactured in
1705 Route 46 Ste 6B, Ledgewood, NJ, United States
Products
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0251-2026Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief